Evidence map›Paper›PMID 27244897›Full record

ArticleOncotarget2016

Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.

Lorena Favaro Pavon, Tatiana Tais Sibov, Daniela Mara de Oliveira, Luciana C Marti, Francisco Romero Cabral, Jean Gabriel de Souza, Pamela Boufleur, Suzana M F Malheiros, Manuel A de Paiva Neto, Edgard Ferreira da Cruz and 2 more

Abstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Knock-Out ofFrontiers in endocrinology · 2021
    Article
  6. Article
  7. Glioblastoma Stem Cells and Comparison of Isolation Methods.Journal of clinical medicine research · 2019
    Article
  8. Tropism of mesenchymal stem cell toward CD133Stem cell research & therapy · 2018
    Article
  9. Review
  10. Article
  11. Article
  12. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lorena Favaro PavonDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.
Tatiana Tais SibovDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.
Daniela Mara de OliveiraDepartment of Genetics and Morphology, Universidade de Brasília, Brasília, Brazil.
Luciana C MartiHospital Israelita Albert Einstein (HIAE), Experimental Research, São Paulo, Brazil.
Francisco Romero CabralHospital Israelita Albert Einstein (HIAE), Experimental Research, São Paulo, Brazil.
Jean Gabriel de SouzaBiochemistry and Biophysics Laboratory, Butantan Institute, Neuro-Oncology Program, São Paulo, Brazil.
Pamela BoufleurBiochemistry and Biophysics Laboratory, Butantan Institute, Neuro-Oncology Program, São Paulo, Brazil.
Suzana M F MalheirosDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.
Manuel A de Paiva NetoDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.
Edgard Ferreira da CruzDiscipline of Nephrology, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.
Ana Marisa Chudzinski-TavassiBiochemistry and Biophysics Laboratory, Butantan Institute, Neuro-Oncology Program, São Paulo, Brazil.
Sérgio CavalheiroDepartment of Neurology and Neurosurgery, Escola Paulista de Medicina-Universidade Federal de São Paulo (EPM-UNIFESP), São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is composed of dividing tumor cells, stromal cells and tumor initiating CD133+ cells. Recent reports have discussed the origin of the glioblastoma CD133+ cells and their function in the tumor microenvironment. The present work sought to investigate the multipotent and mesenchymal properties of primary highly purified human CD133+ glioblastoma-initiating cells. To accomplish this aim, we used the following approaches: i) generation of tumor subspheres of CD133+ selected cells from primary cell cultures of glioblastoma; ii) analysis of the expression of pluripotency stem cell markers and mesenchymal stem cell (MSC) markers in the CD133+ glioblastoma-initiating cells; iii) side-by-side ultrastructural characterization of the CD133+ glioblastoma cells, MSC and CD133+ hematopoietic stem cells isolated from human umbilical cord blood (UCB); iv) assessment of adipogenic differentiation of CD133+ glioblastoma cells to test their MSC-like in vitro differentiation ability; and v) use of an orthotopic glioblastoma xenograft model in the absence of immune suppression. We found that the CD133+ glioblastoma cells expressed both the pluripotency stem cell markers (Nanog, Mush-1 and SSEA-3) and MSC markers. In addition, the CD133+ cells were able to differentiate into adipocyte-like cells. Transmission electron microscopy (TEM) demonstrated that the CD133+ glioblastoma-initiating cells had ultrastructural features similar to those of undifferentiated MSCs. In addition, when administered in vivo to non-immunocompromised animals, the CD133+ cells were also able to mimic the phenotype of the original patient's tumor. In summary, we showed that the CD133+ glioblastoma cells express molecular signatures of MSCs, neural stem cells and pluripotent stem cells, thus possibly enabling differentiation into both neural and mesodermal cell types.

Indexed as

AC133 AntigenAdipocytesAnimalsBiomarkers, TumorBrain NeoplasmsCell DifferentiationCell Line, TumorFetal BloodGlioblastomaHumansImmunophenotypingMaleMesenchymal Stem CellsMicrospheresNeoplastic Stem CellsRatsAC133 AntigenBiomarkers, TumorPROM1 protein, humanCD133+MSC immunophenotypeneurospheresTEMtumorigenesis in vivo

Identifiers

PMID27244897
PMCPMC5130027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.